Revance Therapeutics Inc (FRA:RTI)
€ 3.5 -0.08 (-2.23%) Market Cap: 358.58 Mil Enterprise Value: 642.04 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc at Wells Fargo Virtual Healthcare Conference Transcript

Sep 09, 2020 / 05:20PM GMT
Release Date Price: €23.2 (+1.75%)
Editor

The note (audio in progress) indicates an audio problem. The missing text will be supplied if a replay becomes available.

Unidentified Participant

(Audio in progress) press or media are not permitted to join. If you are a member of the press or media please disconnect at this time. Also please be advised that today's conference is being recorded. Thank you.

Jacob Hughes
Wells Fargo Securities - Analyst

Good afternoon, everyone. We are ready to get started. My name is Jacob Hughes; I am the senior specialty pharmaceuticals analyst at Wells Fargo. Next up I have the pleasure to introduce Revance Therapeutics. We have been behind the story since Mark took over as CEO late last year and has one of the most exciting pipelines in our coverage as the Company transitions some of its pipeline from development stage to commercialization.

From the Company we have CEO, Mark Foley, who will give an updated presentation, as well as Toby, the Chief Financial Officer and IR. If there is enough time at the end of the presentation we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot